Cell Therapeutics launches Pixuvri in europe Cell Therapeutics.

In the E.U., there are 37 approximately, 000 new cases of intense B-cell NHL each year. ‘Patients with late-stage intense NHL who are not eligible for, or who have not responded to, second range therapy, have not a lot of treatment options and a bleak outlook, with typical survival of less than a full year,’ commented Dr. Ruth Pettengell, Consultant Hemato-Oncologist at St George’s Medical center, London and principal investigator of the Phase III EXTEND study. ‘The evidence for Pixuvri demonstrates improved efficacy over current treatment options, but without the cardiotoxicity of anthracyclines. By addressing this unmet need, Pixuvri can be an important new treatment option for physicians treating this combined band of patients.’ Related StoriesHPV study partnership signed between Beckman Coulter and IncellDxLiposomal sizing and the Coulter theory: an interview with Professor Melvin E.Ann Tallant, Ph.D., a professor in the Hypertension and Vascular Research Center – a known fact that motivates them in their research. Peptides, within all animals, are compounds formed by linking one or more amino acids together through the sharing of electrons. They are among the inspiration of life. Peptides can perform a wide range of functions in your body, depending on which proteins are participating. Some can regulate hormones, for instance, while others can possess an antibiotic function.